Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nanexa AB (publ) (NANEXA.ST)
Uppsala, SE
Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for drug administration. Furthermore, Nanexa is progressing NEX-18, a PharmaShell-based candidate specifically designed to address severe conditions such as Myelodysplastic Syndrome and Acute Myeloid Leukemia. The company was established in 2007 and is headquartered in Uppsala, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.54% | -2.62% | -9.62% | -4.21% | +95.83% | -12.53% | +66.27% | +3.98% | -57.93% | -59.35% | -60.44% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+48.4% ★ Q1'26: -43.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+59.4% ★ Q1'26: -34.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-60.1% Q1'26: -321.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-42.8% Q1'26: -828.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-26.1% Q1'26: -97.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+14.9% Q1'26: +15.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.75× Q1'26: -0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
2.37M
est: 2.00M (+18.4%)
|
2.37M
est: 23.00M (-89.7%)
|
2.86M
est: 15.00M (-80.9%)
|
29.33M
est: 53.39M (-45.1%)
|
24.36M
est: 71.30M (-65.8%)
|
36.15M
est: 15.00M (+141.0%)
|
112.20M
112.20M – 112.20M
+648.0% YoY
|
| EBITDA |
-16.28M
est: -1.91M (-751.8%)
|
-32.92M
est: -21.99M (-49.7%)
|
-53.86M
est: -14.34M (-275.6%)
|
-70.79M
est: -41.22M (-71.7%)
|
-18.99M
est: -55.05M (+65.5%)
|
-2.92M
est: -11.58M (+74.8%)
|
-86.62M
-86.62M – -86.62M
-648.0% YoY
|
| EBIT |
-21.49M
est: -2.00M (-974.5%)
|
-35.82M
est: -23.00M (-55.7%)
|
-57.97M
est: -15.00M (-286.5%)
|
-76.02M
est: -47.28M (-60.8%)
|
-24.55M
est: -63.14M (+61.1%)
|
-15.46M
est: -13.28M (-16.4%)
|
-99.36M
-99.36M – -99.36M
-648.0% YoY
|
| Net Income |
-21.74M
est: -12.63M (-72.0%)
|
-36.00M
est: -77.35M (+53.5%)
|
-58.57M
est: -119.41M (+51.0%)
|
-76.40M
|
-24.91M
est: 6.24M (-499.4%)
|
-11.39M
est: 34.30M (-133.2%)
|
—
— – —
-100.0% YoY
|
| SGA |
9.89M
est: 12.08M (-18.2%)
|
15.84M
est: 138.97M (-88.6%)
|
45.31M
est: 90.63M (-50.0%)
|
48.11M
est: 277.99M (-82.7%)
|
45.68M
est: 371.22M (-87.7%)
|
—
est: 78.10M (-100.0%)
|
584.17M
584.17M – 584.17M
+648.0% YoY
|
| EPS |
-1.02
est: -0.09 (-995.6%)
|
-1.01
est: -0.57 (-77.2%)
|
-1.16
est: -0.88 (-31.8%)
|
-1.09
|
-0.18
est: 0.04 (-550.0%)
|
-0.07
est: 0.22 (-133.2%)
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Westberg | Chief Executive Officer | 4M | male |
| Anders Johansson | Co-Founder & Head of Intellectual Property | 996.0K | male |
| Otto Skolling | Director of Business Development | 867.0K | male |
| Joel Hellrup | Head of Pharmaceutical R&D | — | male |
| Marten Rooth | Co-Founder & Chief Technology Officer | — | male |
| Mikael Asp | Head of QA & Special Advisor | — | male |
| Polla Rouf | Head of ALD R&D | — | — |
| Bridget Lacey | Chief Business Officer | — | female |
| Cecilia Danckwardt-Lilliestrom | Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NANEXA.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
